Comparing the current results to its competitors, Candel Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, slower than the combined decrease of the CADL's competitors by -30.52 %, recorded in the same quarter.
Candel Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology sectors, focusing on the development of immuno-oncology therapies for cancer treatment. Its competitors include major pharmaceutical and biotechnology firms such as AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Novartis, Pfizer, Genentech, and Johnson & Johnson, all of which have commercialized or are developing immuno-oncology treatments. Additional competitors developing viral immunotherapies for cancer include Replimune Group, Inc., Amgen Inc., Astellas Pharma, Inc., Istari Oncology Inc., Orca Therapeutics, B.V., CG Oncology, Inc., ImmVira Co., Ltd., IconOVir Bio, Inc., and FerGene, Inc. Potential competitors also encompass academic institutions, government agencies, and other public and private research organizations. Many competitors possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies may also present significant competition, particularly through collaborations with larger firms. Competitors also vie in recruiting personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies. The company’s commercial prospects could be diminished or eliminated if competitors develop safer or more effective products with fewer side effects.
May 23, 2024
Candel Therapeutics, a clinical stage biopharmaceutical company, has recently made significant advancements in the development of multimodal biological immunotherapies to combat cancer. The company s innovative approach aims to address the limitations of current treatment options and improve outcomes for patients with advanced non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors. In this article, we will delve into the key findings and achievements presented by Candel Therapeutics at various medical conferences, shedding light on their potential to revolutionize cancer treatment.Prolonged Overall Survival in NSCLC Trial:Candel Therapeutics has reported promising results from a Phase 2 clin...
April 11, 2024
Candel Therapeutics, a clinical-stage biopharmaceutical company focused on the development of innovative multimodal biological immunotherapies, has achieved significant milestones in the treatment of pancreatic and brain cancers. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Candel s most advanced candidate, CAN-2409, for pancreatic cancer treatment. Additionally, promising results from a Phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer patients have been reported. Furthermore, Candel s herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, has shown promising outcomes in an ongoing Phase 1b clinical trial for r...
April 4, 2024
In an ongoing stride towards innovative cancer treatments, Candel Therapeutics, Inc. - a clinical stage biopharmaceutical firm committed to developing multimodal biological immunotherapies to counter cancer, recently shared promising interim survival data from their ongoing randomized phase 2 clinical trial of the complex CAN-2409 therapy employed to treat non-metastatic pancreatic cancer.Dedicated to the mission of battling cancer, Candel s recent announcements highlight the positive interim results from the clinical trial of CAN-2409 coupled with valacyclovir (prodrug), which is then followed by a standard of care (SoC) chemoradiation and resection. This cutting-edge treatment has primarily been designed t...
March 28, 2024
Candel Therapeutics, a clinical stage biopharmaceutical company, recently presented updated data from an ongoing phase 1b clinical trial of their viral immunotherapy candidate, CAN-3110, during the 5th Glioblastoma Drug Development Summit in Boston, Massachusetts. This article aims to ly outline the key facts and implications of the presentation, shedding light on the potential advancements in the treatment of recurrent high-grade glioma (rHGG).Background:Candel Therapeutics is focused on developing and commercializing viral immunotherapies primarily targeting cancer, including their candidate CAN-3110. This therapy utilizes a replication-competent herpes simplex virus-1 (HSV-1) to harness the patient s immu...
NEEDHAM, Mass. Candel Therapeutics, a biopharmaceutical company based in Massachusetts, announced a significant milestone in its effort to develop an effective treatment for pancreatic ductal adenocarcinoma (PDAC). The Food and Drug Administration (FDA) has granted Fast Track Designation to the company s lead investigational drug CAN-2409, a promising new addition to the global fight against pancreatic cancer. The FDA Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The designation reflects the potential of CAN-2409 to make a significant positive difference for those diagnosed with pancreati...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Candel Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Candel Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
